Jeff is currently Vice-President and Director of Medical Product Development at Apollon Formularies plc and was responsible for the production and manufacturing of all of the Apollon products demonstrated to be successful in killing breast and prostate cancer cells in Apollon’s preclinical independent testing at BIOENSIS laboratories and currently sold by physician prescription in Jamaica. He was also responsible for manufacturing all of the natural biologics based medical products for the cancer clinical trials.
In the event that GHG exercises its option to acquire the entirety of the Apollon assets per the binding Letter of Intent executed between the Parties (for further detail on the transaction, see the news release of January 11, 2023 and March 20, 2023), the Company will look to bring on Mr. Nagel as its Vice-President and Director of Global Manufacturing (“DGM”). As VP and DGM Jeff’s role will be to oversee the Company's global manufacturing operations of the Apollon products, including product development, quality control, and supply chain management, and work closely with the Company's executive team to develop and execute manufacturing strategies that align with the company's overall goals and objectives.
"I am excited to join the team at Global Hemp Group, Inc. and contribute to the growth and success of the company," said Nagel. "I believe that the recent exclusive intellectual property licenses procured from Apollon opens the door for the creation of some amazing and innovative new products in the natural biologics space!”
"Jeff's extensive experience and expertise in manufacturing and product formulation will greatly assist the Company as it talks to manufacturers and distributors about sublicensing and monetizing GHG’s exclusive licenses from Apollon" said Stephen Barnhill, Jr, Interim CEO of Global Hemp Group, Inc. "We are thrilled to have him on board and look forward to working with him to take this segment of our business to the next level."